The T1 eSports collective just lost a major player with Gumayusi's departure. Here's what we know about why he chose to leave ...

The metabolic disorder therapeutics market projects growth to $120.7 billion by 2030 as biotechnology firms pioneer organ-level treatments addressing diabetes, liver disease, and aging-related decline ...

Technically, Nvidia shares trade within an ascending wedge formation as demonstrated using trendline 2 (T2) and trendline 3 ...

December S&P 500 E-Mini futures (ESZ25) are down -0.97%, andDecember Nasdaq 100 E-Mini futures (NQZ25) are down -1.29% this ...

Despite winning LoL Worlds 2025, Gumayusi has announced his departure from T1 after seven years and three World Championships ...

Bills quarterback Josh Allen put on a performance for the ages in his team’s 44–32 win over the Buccaneers on Sunday. The ...

Jaguars running back Travis Etienne Jr. notched two touchdowns and 73 rushing yards on a team-high 19 carries, en route to ...

This study investigates the folding and unfolding behavior of the doubly knotted protein TrmD-Tm1570, providing insight into the molecular mechanisms underlying protein knotting. The findings reveal ...

Altimmune’s pemvidutide shows promising Phase IIb MASH results; see key benefits, risks, and a bullish outlook. Read here for ...

GLP-1 RAs, particularly semaglutide and tirzepatide, outperform older medications in achieving significant weight loss in adults with and without type 2 diabetes. Semaglutide and tirzepatide met ...

Pluristyx’s platform technology was developed specifically to overcome this challenge. This Breakthrough T1D collaboration will fund the use of precise gene editing to engineer Pluristyx’s exclusively ...

During a live event, Thomas G. Martin, MD, discussed updated findings from the CARTITUDE-1 trial of cilta-cel and what they signify for patients with no disease progression at 5 years.